NovaBay Pharmaceuticals, Inc. (AMEX:NBY) has scheduled a conference call for 12th November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.novabay.com
To participate on the live call, please dial 866-677-7731 U.S. or 480-405-6745 Toll Number
Earnings Expectation
NovaBay Pharmaceuticals, Inc. biopharmaceutical firm, is expected to report third quarter earnings results, after market close, on Thursday 12th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.04 per share from revenue of $ 2.52 million. Looking ahead, the full year loss are expected at $ 0.25 per share on the revenues of $ 11.36 million.
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc.
